The North Carolina Biotechnology Center has announced the five sponsoring companies chosen for the first year of its Industrial Fellowship Program.
The North Carolina Biotechnology Center has announced the five sponsoring companies chosen for the first year of its Industrial Fellowship Program. The companies chosen are:
A total of 18 companies applied for the program, which pays two years of salary and benefits for a postdoctoral researcher with academic-only laboratory experience to work in an industrial setting. Additionally, the industrial fellows will have access to programs in business, intellectual property, regulatory affairs, and other areas to complement their training. Fellows selected and hired by sponsoring companies will begin on October 15. The industrial fellowship program is designed to fill a gap for scientists in need of industry experience as well as for companies in need of scientific expertise. Few companies offer transitional opportunities, and PhD scientists coming out of academia are often dismissed as being overqualified for technical jobs but not qualified enough for senior positions.
For more information on the program please visit www.ncbiotech.org/fellowship.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Filter Sizing for Process Optimization in Life Sciences Sterile Filtration
April 24th 2025Bench-scale filterability studies play a critical role in optimizing sterile filtration in biopharmaceutical manufacturing. By guiding the selection and sizing of filters, these studies help streamline processes, improve scalability, and reduce costs. Through data-driven case studies, this paper highlights how the strategic use of pre-filters and membrane materials can maximize throughput and minimize filter fouling.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.